Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo - PubMed (original) (raw)
Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo
T Yamawaki et al. J Am Coll Cardiol. 1998 Sep.
Free article
Abstract
Objectives: This study was designed to examine whether or not intramural delivery of ST638 (a specific tyrosine kinase inhibitor) with biodegradable stent can suppress the restenotic changes of the coronary artery in vivo.
Background: Clinical and animal studies demonstrated that restenosis after coronary intervention results from a combined effect of neointimal formation and geometric remodeling (decrease in total cross-sectional area). Thus, the most effective strategy to prevent the restenosis appears to inhibit both the neointimal formation and geometric remodeling by antiproliferative agent and stent, respectively. We have previously shown that ST638 markedly suppresses the restenotic changes of the porcine coronary artery when applied from the adventitial site.
Methods: A poly-L-lactic acid biodegradable stent was coated with either ST638 (0.8 mg) or equimolar of its inactive metabolite, ST494. A pair of these stents were implanted alternatively in the left anterior descending or circumflex coronary artery in pigs (n=6). Three weeks after the procedure, coronary stenosis was assessed by angiography followed by histological examination.
Results: Coronary stenosis was significantly less at the ST638 stent site than at the ST494 stent site (47+/-5% vs. 25+/-4%, p < 0.01). Histological examination also showed that the extent of neointimal formation and that of geometric remodeling were significantly less at the ST638 stent site than at the ST494 stent site (p < 0.05).
Conclusions: These results indicate that intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent overcomes the proliferative stimuli caused by balloon injury, the stent itself, and the drug coating on the stent, resulting in the suppression of the restenotic changes of the coronary artery in vivo. This strategy might also be useful in the clinical setting in humans.
Similar articles
- Tyrosine kinase inhibitor suppresses the (re) stenotic changes of the coronary artery after balloon injury in pigs.
Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Owada MK, Shiraishi T, Kuga T, Egashira K, Takeshita A. Fukumoto Y, et al. Cardiovasc Res. 1996 Dec;32(6):1131-40. doi: 10.1016/s0008-6363(96)00178-2. Cardiovasc Res. 1996. PMID: 9015416 - Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.
Banai S, Gertz SD, Gavish L, Chorny M, Perez LS, Lazarovichi G, Ianculuvich M, Hoffmann M, Orlowski M, Golomb G, Levitzki A. Banai S, et al. Cardiovasc Res. 2004 Oct 1;64(1):165-71. doi: 10.1016/j.cardiores.2004.06.013. Cardiovasc Res. 2004. PMID: 15364624 - Paradoxical effects of aurintricarboxylic acid and RG-13577: acute thrombosis and in-stent stenosis in a passive-coated stent.
Strehblow C, Sperker W, Hevesi A, Garamvölgyi R, Petrasi Z, Shirazi M, Sylvén C, Weiss T, Lotan C, Pugatsch T, Ben-Sasson SA, Orlowski M, Glogar D, Gyöngyösi M. Strehblow C, et al. J Endovasc Ther. 2006 Feb;13(1):94-103. doi: 10.1583/05-1641.1. J Endovasc Ther. 2006. PMID: 16445329 - Antithrombotic stent coatings: hirudin/iloprost combination.
Alt E, Seliger C. Alt E, et al. Semin Interv Cardiol. 1998 Sep-Dec;3(3-4):177-83. Semin Interv Cardiol. 1998. PMID: 10406690 Review. - Comparative pathology: radiation-induced coronary artery disease in man and animals.
Virmani R, Farb A, Carter AJ, Jones RM. Virmani R, et al. Semin Interv Cardiol. 1998 Sep-Dec;3(3-4):163-72. Semin Interv Cardiol. 1998. PMID: 10406688 Review.
Cited by
- New drug-eluting stent concepts.
Wessely R. Wessely R. Nat Rev Cardiol. 2010 Apr;7(4):194-203. doi: 10.1038/nrcardio.2010.14. Epub 2010 Mar 2. Nat Rev Cardiol. 2010. PMID: 20195268 Review. - Novel biodegradable stents for benign esophageal strictures following endoscopic submucosal dissection.
Saito Y, Tanaka T, Andoh A, Minematsu H, Hata K, Tsujikawa T, Nitta N, Murata K, Fujiyama Y. Saito Y, et al. Dig Dis Sci. 2008 Feb;53(2):330-3. doi: 10.1007/s10620-007-9873-6. Epub 2007 Aug 23. Dig Dis Sci. 2008. PMID: 17713855 - Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with benign esophageal stenosis.
Saito Y, Tanaka T, Andoh A, Minematsu H, Hata K, Tsujikawa T, Nitta N, Murata K, Fujiyama Y. Saito Y, et al. World J Gastroenterol. 2007 Aug 7;13(29):3977-80. doi: 10.3748/wjg.v13.i29.3977. World J Gastroenterol. 2007. PMID: 17663513 Free PMC article. - Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers.
Doyle B, Holmes DR Jr. Doyle B, et al. Med Devices (Auckl). 2009;2:47-55. doi: 10.2147/mder.s5617. Epub 2009 Nov 10. Med Devices (Auckl). 2009. PMID: 22915914 Free PMC article. - Local drug delivery to prevent restenosis.
Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC. Seedial SM, et al. J Vasc Surg. 2013 May;57(5):1403-14. doi: 10.1016/j.jvs.2012.12.069. J Vasc Surg. 2013. PMID: 23601595 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical